

## LAB1

Sample ID	Age	Sex	Disease type	T-Stage	N-Stage	M-Stage
1a_DIS_1	68	m	Oropharynx Ca	3	2	0
1a_DIS_2	56	m	Larynx Ca	1	0	0
1a_DIS_3	59	m	Oropharynx Ca	1	2	0
1a_DIS_4	50	m	Hypopharynx Ca	2	2	0
1a_DIS_5	49	m	Oropharynx Ca	2	2	0
1a_DIS_6	66	m	Oropharynx Ca	3	1	0
1a_DIS_7	80	m	Larynx Ca	2	0	0
1a_DIS_8	77	m	oral cavity Ca	1	0	x
1a_DIS_9	69	m	Hypopharynx Ca	3	0	0
1a_DIS_10	66	m	Oropharynx Ca	3	2	0
1a_DIS_11	64	m	Oropharynx Ca	2	2	0
1a_DIS_12	65	m	Larynx Ca	4	2	x
1a_DIS_13	72	m	Larynx Ca	1	0	0
2_DIS_1	62	m	Oropharynx Ca	1	3	0
2_DIS_2	58	w	Hypopharynx Ca	4	2	0
2_DIS_3	85	m	Larynx Ca	1	0	0
2_DIS_4	61	w	Larynx Ca	1	0	0
2_DIS_5	76	m	Oral cavity CA	1	0	x
2_DIS_6	78	w	Oropharynx Ca	2	0	0
2_DIS_7	60	m	Larynx Ca	1	0	0
2_DIS_8	57	w	Larynx Ca	3	2	1
2_DIS_9	64	w	Larynx Ca	2	0	x
2_DIS_10	73	m	Larynx Ca	3	2	0
2_DIS_11	70	m	Larynx Ca	1	0	0
2_DIS_12	56	w	Oropharynx Ca	3	2	0
2_DIS_13	64	m	Larynx Ca	1	0	0
3_DIS_1	67	m	Larynx Ca	2	2	0
3_DIS_2	61	m	Oropharynx Ca	1	0	0
3_DIS_3	60	w	Oral cavity CA	1	2	0
3_DIS_4	56	m	Nasopharynx	2	0	0
3_DIS_5	73	w	Oropharynx Ca	2	1	0
3_DIS_6	61	m	Oropharynx Ca	1	1	0
3_DIS_7	72	m	Oropharynx Ca	2	2	0
3_DIS_8	66	m	Larynx Ca	4	2	0
3_DIS_9	46	m	Nasopharynx	2	1	0
3_DIS_10	72	m	Oropharynx Ca	2	2	x
3_DIS_11	58	w	Oropharynx	1	1	0
3_DIS_12	78	w	Oropharynx	4	2	0
3_DIS_13	61	m	Larynx Ca	1	0	0
Mean Age/stabw	65	9				

Sample ID	Age	Sex	Disease type
1a_CTR_1	53	m	employee
1a_CTR_2	86	m	state after cyst glandula parotis
1a_CTR_3	61	m	Hearing impaired
1a_CTR_4	59	f	employee
1a_CTR_5	52	m	concha hyperplasia
1a_CTR_6	83	m	hearing impaired (CI)
1a_CTR_7	91	m	epistaxis
1a_CTR_8	54	m	concha hyperplasia
1a_CTR_9	68	m	state after leukoplakia
1a_CTR_10	49	m	employee
1b_CTR_1	38	w	employee
1b_CTR_2	63	w	employee
1b_CTR_3	29	w	employee
1b_CTR_4	38	m	employee
1b_CTR_5	33	m	employee
2_CTR_1	57	m	state after thyroid nodules (euthyroidism)
2_CTR_2	63	f	employee
2_CTR_3	41	m	employee
2_CTR_4	61	f	employee
2_CTR_5	48	m	state after thyroid nodules (euthyroidism)
2_CTR_6	54	m	employee
2_CTR_7	56	m	cervical lymphadenopathy
2_CTR_8	40	m	concha hyperplasia
2_CTR_9	39	m	state after adenom of Glandula parotis
2_CTR_10	60	m	state after T4 Larynx Ca 2014
Mean Age/stabw	55	16	

**LAB 2****STEP 1a**

Sample ID	AGE	SEX	Disease type	ER	PgR	Grade (invasive)	Her2	Ethnicity	BMI	Co - morbidities
Lab2Dis1	53	F	Invasive Breast cancer	8	6	2	2+ FISH negative	White	20	Nil
Lab2Dis2	65	F	Invasive Breast cancer	8	4	1	2+ FISH negative	White	28	Nil
Lab2Dis3	65	F	Invasive Breast cancer	8	8	2	0 negative	White	33	Asthma
Lab2Dis4	59	F	Invasive Breast cancer	8	8	1	1+ negative	White	34	COPD
Lab2Dis5	50	F	Invasive Breast cancer	8	8	1	1+ negative	White	33	NIDDM
Lab2Dis6	61	F	Invasive Breast cancer	7	3	3	3+ positive	White	27	Nil
Lab2Dis7	41	F	Invasive Breast cancer	8	8	2	2+ FISH negative	White	28	Nil
Lab2Dis8	42	F	Invasive Breast cancer	7	7	2	1+ negative	White	20	Nil
Lab2Dis9	52	F	Invasive Breast cancer	8	5	2	2+ FISH negative	White	27	Nil
Lab2Dis10	51	F	Invasive Breast cancer	7	7	1	0 negative	White	24	Nil
Lab2Dis11	63	F	Invasive Breast cancer	8	8	2	1+ negative	White	32	Hypothyroidism
Lab2Dis12	64	F	Invasive Breast cancer	8	8	2	2+ FISH negative	White	32	NIDDM, Asthma
Lab2CTR1	61	F	Healthy Control							
Lab2CTR2	55	F	Healthy Control							
Lab2CTR3	44	F	Healthy Control							
Lab2CTR4	54	F	Healthy Control							
Lab2CTR5	45	F	Healthy Control							
Lab2CTR6	43	F	Healthy Control							
Lab2CTR7	47	F	Healthy Control							
Lab2CTR8	51	F	Healthy Control							
Lab2CTR9	51	F	Healthy Control							
Lab2CTR10	52	F	Healthy Control							

**STEP 1b**

Lab2CTR11	>40	F	Healthy Control							
Lab2CTR12	>40	F	Healthy Control							
Lab2CTR13	>40	F	Healthy Control							

**STEP 2**

Lab2Dis13	>40	F	Lobular	8	8	2	FISH neg	White		
Lab2Dis14	>40	F	Mixed- NST/Mucinous	8	5	2	1+ neg	White		
Lab2Dis15	>40	F	NST	7	8	2	1+ neg	White		
Lab2Dis16	>40	F	NST	7	8	2	1+ neg	White		
Lab2Dis17	>40	F	NST	8	8	2	FISH neg	White		
Lab2Dis18	>40	F	DCIS	8		High grade		White		
Lab2Dis19	>40	F	NST	7	6	1	0 neg	White		
Lab2Dis20	>40	F	NST	8	7	2	1+ neg	White		
Lab2Dis21	>40	F	DCIS	8		High grade		White		
Lab2Dis22	>40	F	Lobular	8	7	2	1+ neg	White		
Lab2Dis23	>40	F	NST	8	8	2	FISH neg	White		
Lab2Dis24	>40	F	NST	8	7	1	1+ neg	White		
Lab2CTR14	>40	F	Healthy Control							
Lab2CTR15	>40	F	Healthy Control							
Lab2CTR16	>40	F	Healthy Control							
Lab2CTR17	>40	F	Healthy Control							
Lab2CTR18	>40	F	Healthy Control							
Lab2CTR19	>40	F	Healthy Control							
Lab2CTR20	>40	F	Healthy Control							
Lab2CTR21	>40	F	Healthy Control							
Lab2CTR22	>40	F	Healthy Control							
Lab2CTR23	>40	F	Healthy Control							

## LAB 3

## Phase 1C

Sample ID	AGE	SEX	Disease type	Grade (invasive)	Ethnicity	BMI	Co - morbidities
Lab3DIS1	58	M	Glioblastoma	IV	unknown	1,82m 79kg	Psoriasis, tosio testis, spermatocele, artritis psoriatica, hemorroids, essential hypertension
Lab3DIS2	64	M	Glioblastoma	IV	unknown	1,74m 96,5kg	urolithiasis, melanoma, carpal tunnelsyndrome, vasectomy. NB: brother of N17-07
Lab3DIS3	63	M	Glioblastoma	IV	unknown	1,76m 88,4kg	depression, diabetes mellitus type 2, polyneuropathy. NB: brother of N17-06
Lab3DIS4	26	F	Dysembryoplastic neuroepithelial tumor	I	unknown	1,71m 51kg	prior surgery 2007
Lab3DIS5	67	F	Glioblastoma	IV	unknown	1,62m 58,1kg	hypothyreoidy
Lab3DIS6	67	F	Diffuse astrocytoma	II	unknown	1,62m 75kg	Ehlers Danlos syndrome, cholesteatoma, abdominal hysterectomy
Lab3DIS7	67	M	Glioblastoma	IV	unknown	1,8m 119,2kg	subretinal neovascularisation treated with avastin injections, analasys for MI
Lab3DIS8	22	M	Anaplastic astrocytoma	III	unknown	1,75m 59kg	previous glioma resectie 2014 (N14-05), appendectomie, clavicular fracture
Lab3DIS9	60	M	Glioblastoma	IV	unknown	1,72m 118kg	cervical fracture, carpal tunnel syndrome
Lab3DIS10	59	F	Anaplastic oligodendroglioma	III	unknown	1,67m 64kg	prior glioma surgery 2006, folowed by Temozolomide and radiotherapy. Prior uterusextirpation and unilateral adnectomy in 2000
Lab3CTR1	60	M	Healthy Control				
Lab3CTR2	46	M	Healthy Control				
Lab3CTR3	63	M	Healthy Control				
Lab3CTR4	58	M	Healthy Control				
Lab3CTR5	68	F	Healthy Control				
Lab3CTR6	64	M	Healthy Control				
Lab3CTR7	69	F	Healthy Control				
Lab3CTR8	68	M	Healthy Control				
Lab3CTR9	55	M	Healthy Control				
Lab3CTR10	64	M	Healthy Control				
Lab3CTR11	63	M	Healthy Control				
Lab3CTR12	62	F	Healthy Control				
Lab3CTR13	58	F	Healthy Control				

## Phase 2A

Lab3CTRa	<40	F	Healthy Control
Lab3CTRb	<40	F	Healthy Control
Lab3CTRc	<40	F	Healthy Control

## LAB 4

## Phase 1C

Sample ID	AGE	SEX	Disease type	Stage	Primary	Metastasis	BRAF mutation status	Ethnicity	Co - morbidities
Lab4Dis1	79	M	Malignant melanoma	IB	plantar	no	unknown	Caucasian	Diabetes, Hypothyreosis
Lab4Dis2	84	F	Malignant melanoma	IB	cheek	no	unknown	Caucasian	Hypothyreosis, Diabetes, art. Hypertension
Lab4Dis3	60	M	Malignant melanoma	IV	forearm	LN, Lung, Pleura and C-Kit mutated; NR		Caucasian	Hepatitis C (successfully treated)
Lab4Dis4	65	F	Malignant melanoma	IB	lower leg	no	unknown	Caucasian	Hypothyreosis, Asthma
Lab4Dis5	38	F	Malignant melanoma	IIIB	unknown	LN	unknown	Caucasian	none known
Lab4Dis6	60	F	Malignant melanoma	IIC	thigh	no	unknown	Caucasian	none known
Lab4Dis7	73	M	Malignant melanoma	IIB	foot	no	unknown	Caucasian	Art. hypertension
Lab4Dis8	49	M	Malignant melanoma	IV	paravertebral	N, Lung, soft part	not done	Caucasian	none known
Lab4Dis9	39	M	Malignant melanoma	IIIA	Capillitium	no	not done	Caucasian	none known
Lab4Dis10	79	M	Malignant melanoma	III	Nose	no	and C-Kit mutated; NR	Caucasian	Art. hypertension
Lab4Dis11	56	F	Malignant melanoma	IV	upper arm	Imonal, LN, cereb	BRAF mutated V600 E	Caucasian	Hypothyreosis, migraine

Lab4CTR1	21	F	Healthy Control
Lab4CTR2	52	M	Healthy Control
Lab4CTR3	57	M	Healthy Control
Lab4CTR4	60	M	Healthy Control
Lab4CTR5	42	M	Healthy Control
Lab4CTR6	45	F	Healthy Control
Lab4CTR7	54	M	Healthy Control
Lab4CTR8	41	F	Healthy Control
Lab4CTR9	45	F	Healthy Control
Lab4CTR10	52	F	Healthy Control
Lab4CTR11	27	F	Healthy Control

## Phase 1C assays

Lab4Dis12	44	M	Malignant melanoma	IV	substernal	LK, cerebral	BRAF mutated	Caucasian	Art. hypertension
Lab4Dis13	49	M	Malignant melanoma	IIIA	scapulär	LK	not done	Caucasian	Basalzellkarzinom
Lab4Dis14	64	M	Malignant melanoma	IIIA	Abdomen	LK	unknown	Caucasian	Diabetes, art. hypertension, ocular hypertension
Lab4Dis15	35	M	Malignant melanoma	IIIA	Flank	LK	not done	Caucasian	None known
Lab4Dis16	38	M	Malignant melanoma	IV	lower leg	Intestinum, LK	WT, C-KIT WT, NRAS m	Caucasian	None known
Lab4Dis17	48	M	Malignant melanoma	IIIA	Flank	LK	Q61R; TERT Prom. 1,	Caucasian	None known
Lab4Dis18	71	M	Malignant melanoma	IB	forehead	No	unknown	Caucasian	art. hypertension, hypothyreosis
Lab4Dis19	82	F	Malignant melanoma	IIIB	forearm	LK	unknown	Caucasian	art. hypertension, Insomnia
Lab4Dis20	84	F	Malignant melanoma	IB	cheek	no	unknown	Caucasian	Hypothyreosis, Diabetes, art. Hypertension
Lab4Dis21	78	M	Malignant melanoma	IB	Lumbal	No	unknown	Caucasian	Atrial fibrillation, Hypertonus, aortic valve replacement in 2011

**LAB 5**

**no patients from this lab are included in this manuscript**

--

## LAB 6

### Phase 1C

Sample ID	AGE	SEX	Disease type	Clinical grade	Histopathological grade	Ethnicity	Co - morbidities
Lab6Dis1	58	M	Colorectal Cancer		2	2 caucasian	Obesity
Lab6Dis2	89	F	Colorectal Cancer		2	2 caucasian	Diabetes Mellitus
Lab6Dis3	67	F	Colorectal Cancer		2	2 caucasian	nil
Lab6Dis4	76	F	Colorectal Cancer		3	2 caucasian	Obesity
Lab6Dis5	62	M	Colorectal Cancer		2	2 caucasian	Hypertension
Lab6Dis6	86	M	Colorectal Cancer		2	2 caucasian	Hypertension
Lab6Dis7	43	F	Colorectal Cancer		2	2 caucasian	nil
Lab6Dis8	49	F	Colorectal Cancer		1	1 caucasian	Hepatosteatosi
Lab6Dis9	62	M	Colorectal Cancer		3	2 caucasian	nil
Lab6Dis10	61	M	Colorectal Cancer		2	2 caucasian	Nephrolithiasis and pollen allergy
Lab6Dis11	61	M	Colorectal Cancer		2	3 caucasian	Nephrolithiasis
Lab6Dis12	54	M	Colorectal Cancer		2	2 caucasian	Hypertension
Lab6CTR1	55	M	Healthy Control				
Lab6CTR2	52	M	Healthy Control				
Lab6CTR3	48	M	Healthy Control				
Lab6CTR4	51	M	Healthy Control				
Lab6CTR5	56	M	Healthy Control				
Lab6CTR6	52	F	Healthy Control				
Lab6CTR7	54	F	Healthy Control				
Lab6CTR8	47	F	Healthy Control				
Lab6CTR9	58	M	Healthy Control				
Lab6CTR10	52	M	Healthy Control				
Lab6CTR11	54	M	Healthy Control				
Lab6CTR12	48	F	Healthy Control				
Lab6CTR13	51	F	Healthy Control				
Lab6CTR14	53	F	Healthy Control				
Lab6CTR15	50	M	Healthy Control				

## LAB 7

## Phase 1C

Sample ID	AGE	SEX	Disease type	ER	PgR	Grade (invasive)	Her2	Ethnicity	BMI	Co - morbidities	histological subtype	FIGO stage	initials	weight	height
Lab7Dis1	66	F	ovarian carcinoma	positive	NA	G3	NA	caucasian	30,46	ischemic heart disease, left breast cancer in the past, hypertension, Irritable bowel syndrome	serous	IIIC	BZS	77	159
Lab7Dis2	57	F	ovarian carcinoma	NA	NA	G2	NA	caucasian	30,00	Hypothyroidism in euthyroidism, hypertension	serous	IV	MB	73	156
Lab7Dis3	68	F	ovarian carcinoma	NA	NA	G2	NA	caucasian	19,91	cervico-shoulder syndrome	serous	IIIC	RH	46	152
Lab7Dis4	64	F	ovarian carcinoma	NA	NA	G3	NA	caucasian	25,81	Hyperthyroidism, Hypertension, Persistent Atrial Fibrillation, Heart failure II degree NYHA	serous	IV	EB	62	155
Lab7Dis5	68	F	ovarian carcinoma	positive	negative	G3	negative	caucasian	31,56	diabetes type II	serous	IV	BSM	71	150
Lab7Dis6	51	F	ovarian carcinoma	NA	NA	G3	NA	caucasian	29,41	Dermatomyositis . Hypothyroidism in euthyreosis. Depression.	serous	IIIC	RT	84	169
Lab7Dis7	65	F	primary peritoneal serous carcinoma	positive	positive	G3	NA	caucasian	23,83	ischemic heart disease, myocardial infarction in the past	serous	IIIC	MH	61	160
Lab7Dis8	47	F	ovarian carcinoma	NA	NA	G3	NA	caucasian	24,03	ulcerative colitis	serous	IIIC	MB	60	158
Lab7Dis9	49	F	ovarian carcinoma	NA	NA	G3	NA	caucasian	26,30	Hypothyroidism in euthyroidism	serous	IIIC	MP	64	156
Lab7Dis10	47	F	ovarian carcinoma	NA	NA	G3	NA	caucasian	22,83	NR	serous	IIIC	JK	57	158
Lab7CTR1	35	F	Healthy Control												
Lab7CTR2	36	F	Healthy Control												
Lab7CTR3	28	F	Healthy Control												
Lab7CTR4	32	F	Healthy Control												
Lab7CTR5	27	F	Healthy Control												
Lab7CTR6	54	F	Healthy Control												
Lab7CTR7	57	F	Healthy Control												
Lab7CTR8	40	F	Healthy Control												
Lab7CTR9	38	F	Healthy Control												
Lab7CTR10	35	F	Healthy Control												
Lab7CTR11	35	F	Healthy Control												
Lab7CTR12	38	F	Healthy Control												

**LAB 8****Phase 1C**

Sample ID	AGE	SEX	leukocytes/nl	INR	Bilirubin (n	GOT U/l	GPT U/l	HBsAg IU/ml	antiHBs IU, HBeAg	anti-HBe	HBV DNS
Lab8Dis1		45 F	5,73	1,04	0,7	17	16	12096	0 neg	pos	2100
Lab8Dis2		46 M	4,36	0,97	0,9	54	44	9491	0 neg	pos	1063
Lab8Dis3		38 M	7,2		1,4	23	33	1269	0 neg	pos	<10
Lab8Dis4		32 M	4,68	1,02	1	18	24	26484	0 neg	pos	1647
Lab8Dis5		54 F	8,06		0,6	27	33	17691	0 neg	pos	1779
Lab8Dis6		44 M	7,4	1,08	0,4	24	22	6,27	0 neg	pos	0
Lab8Dis7		64 F	5,68	0,98	0,4	29	33	3485	0 neg	pos	584
Lab8Dis8		50 M	7,02	0,99	0,6	57	60	2,42	10 neg	pos	118
Lab8Dis9		38 M	6,72	1,01	0,4	27	25	1345	0 neg	pos	<10
Lab8Dis10		34 M	4,68	1,02	0,7	36	60	10023	0 pos	neg	1128
Lab8Dis11		54 F	4,85	1,05	0,4	25	20	3557	0 neg	pos	2009
Lab8CTR1		36 M									
Lab8CTR2		28 M									
Lab8CTR3		34 M									
Lab8CTR4		28 M									
Lab8CTR5		35 M									
Lab8CTR6		31 M									
Lab8CTR7		48 M									
Lab8CTR8		29 M									
Lab8CTR9		32 M									
Lab8CTR10		36 M									
Lab8CTR11		29 M									
Lab8CTR12		32 M									



**LAB 9****Phase 1C**

Sample ID	AGE	SEX	Disease type	CD4 mm3/ml (%)	Viremia (H time on ART tre time since undetectable viremia (years))		
Lab9Dis1	57	M	HIV-1	815 (36)	<50	21	10
Lab9Dis2	63,2	M	HIV-1	809 (32)	<50	10	9
Lab9Dis3	64,7	F	HIV-1	839 (21)	<50	10	9
Lab9Dis4	26,4	F	HIV-1	682 (31)	<50	3	3
Lab9Dis5	48,3	M	HIV-1	614 (35)	<50	3	2
Lab9Dis6	55,9	F	HIV-1	1651 (39)	<50	20	3
Lab9Dis7	56,1	F	HIV-1	970 (56)	<50	25	9
Lab9Dis8	69	M	HIV-1	394 (29)	<50	25	10
Lab10Dis9	61	M	HIV-1	998 (44)	<50	25	11
Lab11Dis10	64,9	M	HIV-1	450 (24)	<50	23	3
Lab9CTR1	na	na	Healthy Control				
Lab9CTR2	na	na	Healthy Control				
Lab9CTR3	na	na	Healthy Control				
Lab9CTR4	na	na	Healthy Control				
Lab9CTR5	na	na	Healthy Control				
Lab9CTR6	na	na	Healthy Control				
Lab9CTR7	na	na	Healthy Control				
Lab9CTR8	na	na	Healthy Control				
Lab9CTR9	na	na	Healthy Control				
Lab9CTR10	na	na	Healthy Control				
Lab9CTR11	na	na	Healthy Control				

**LAB 10****Phase 1C**

Sample ID	AGE	SEX	Disease type	Antiretroviral therapy	Viremia (cp/mL)	CD4 cells/ $\mu$ L (%)	CD8 cells/ $\mu$ L (%)	Ethnicity	Co - morbidities
Lab10Dis1	51	F	HIV-1 infection	NO	25770	866 (30.3)	1422 (49.8)	Black	None
Lab10Dis2	29	M	HIV-1 infection	NO	153770	664 (24.2)	1634 (59.6)	White	None
Lab10Dis3	37	M	HIV-1 infection	NO	861828	79 (13)	335 (55)	White	Psoriasis
Lab10Dis4	35	M	HIV-1 infection	NO	19544	368 (33.9)	521 (48)	White	None
Lab10Dis5	28	M	HIV-1 infection	NO	589504	24 (2.9)	589 (70.6)	White	None
Lab10Dis6	52	M	HIV-1 infection	NO	22335	10 (1.1)	354 (38.4)	Black	None
Lab10Dis7	27	F	HIV-1 infection	NO	107528	333 (17.3)	1156 (60.1)	Black	None
Lab10Dis8	53	M	HIV-1 infection	NO	897478	69 (6.6)	497 (47.4)	White	None
Lab10Dis9	28	F	HIV-1 infection	NO	802	579 (27.7)	1142 (54.7)	Black	None
Lab10Dis10	22	F	HIV-1 infection	NO	23142	535 (25.9)	1028 (49.7)	Black	None
Lab10CTR1	28	M	Healthy Control						
Lab10CTR2	29	M	Healthy Control						
Lab10CTR3	50	F	Healthy Control						
Lab10CTR4	29	M	Healthy Control						
Lab10CTR5	35	M	Healthy Control						
Lab10CTR6	54	M	Healthy Control						
Lab10CTR7	24	F	Healthy Control						
Lab10CTR8	36	M	Healthy Control						
Lab10CTR9	23	F	Healthy Control						
Lab10CTR10	30	F	Healthy Control						

**Phase 2CA**

Lab10CTR11	36	M	Healthy Control
Lab10CTR12	31	M	Healthy Control
Lab10CTR13	37	F	Healthy Control

**LAB 11****Phase 1C**

Sample ID	AGE	SEX	Disease type	PASI
LAB11DIS1	36	F	psoriasis	8
LAB11DIS2	55	M	psoriasis	12
LAB11DIS3	54	F	psoriasis	6
LAB11DIS4	50	M	psoriasis	24
LAB11DIS5	41	F	psoriasis	14
LAB11DIS6	25	F	psoriasis	12
LAB11DIS7	31	F	psoriasis	8
LAB11DIS8	31	M	psoriasis	24
LAB11DIS9	22	M	psoriasis	26
LAB11DIS10	18	M	psoriasis	8
LAB11DIS11	26	M	psoriasis	12
LAB11DIS12	57	M	psoriasis	38
LAB11DIS13	20	F	psoriasis	8
LAB11DIS14	29	M	psoriasis	12
LAB11CTR1	25	F	healthy donor	
LAB11CTR2	49	F	healthy donor	
LAB11CTR3	38	M	healthy donor	
LAB11CTR4	43	F	healthy donor	
LAB11CTR5	29	F	healthy donor	
LAB11CTR6	21	M	healthy donor	
LAB11CTR7	38	M	healthy donor	
LAB11CTR8	27	F	healthy donor	
LAB11CTR9	37	M	healthy donor	
LAB11CTR10	35	M	healthy donor	
LAB11CTR11	41	M	healthy donor	
LAB11CTR12	30	F	healthy donor	
LAB11CTR13	27	M	healthy donor	
LAB11CTR14	28	M	healthy donor	

**Phase 2A**

Sample ID	AGE	SEX	Disease type
LAB11CT	50	F	healthy donor
LAB11CT	45	F	healthy donor
LAB11CT	33	F	healthy donor
LAB11CT	30	F	healthy donor
LAB11CT	38	M	healthy donor

**Phase 3A**

Sample ID	AGE	SEX	Disease type	PASI
LAB11DI!	61	M	psoriasis	27
LAB11DI!	30	M	psoriasis	18
LAB11DI!	29	F	psoriasis	25
LAB11DI!	35	M	psoriasis	12
LAB11DI!	26	M	psoriasis	17
LAB11DI!	20	F	psoriasis	12
LAB11DI!	55	M	psoriasis	20
LAB11DI!	27	F	psoriasis	22
LAB11DI!	37	F	psoriasis	12
LAB11DI!	25	M	psoriasis	24
LAB11DI!	27	F	psoriasis	16
LAB11CT	29	M	healthy donor	
LAB11CT	28	M	healthy donor	
LAB11CT	33	M	healthy donor	
LAB11CT	51	M	healthy donor	
LAB11CT	40	F	healthy donor	
LAB11CT	38	M	healthy donor	
LAB11CT	45	F	healthy donor	
LAB11CT	29	M	healthy donor	
LAB11CT	37	M	healthy donor	
LAB11CT	31	M	healthy donor	
LAB11DI!	26	F	psoriasis	32
LAB11DI!	35	M	psoriasis	10
LAB11DI!	37	M	psoriasis	19
LAB11DI!	72	M	psoriasis	17
LAB11DI!	45	M	psoriasis	12
LAB11DI!	35	M	psoriasis	18
LAB11DI!	33	M	psoriasis	20
LAB11DI!	56	M	psoriasis	19
LAB11DI!	45	M	psoriasis	12

**LAB 12****Phase 1C**

Sample ID	AGE	SEX	Condition	Notes
Lab12Dis1	40	Female	day 2 after vaccination	1. All subjects are healthy individuals 2. Donor 1-4 were vaccinated with tick-borne encephalitis vaccine 3. Donor 5-14 were vaccinated with yellow fever vaccine 4. Ctrl and Dis samples are donor-matched.
Lab12Dis2	27	Male	day 2 after vaccination	
Lab12Dis3	25	Male	day 2 after vaccination	
Lab12Dis4	25	Male	day 2 after vaccination	
Lab12Dis5	26	Male	day 2 after vaccination	
Lab12Dis6	29	Male	day 2 after vaccination	
Lab12Dis7	25	Male	day 2 after vaccination	
Lab12Dis8	25	Male	day 2 after vaccination	
Lab12Dis9	24	Male	day 2 after vaccination	
Lab12Dis10	24	Male	day 2 after vaccination	
Lab12Dis11	27	Male	day 2 after vaccination	
Lab12Dis12	26	Male	day 2 after vaccination	
Lab12Dis13	27	Female	day 2 after vaccination	
Lab12Dis14	27	Female	day 2 after vaccination	
Lab12CTR1	40	Female	Before vaccination	1. All subjects are healthy individuals 2. Donor 1-4 were vaccinated with tick-borne encephalitis vaccine 3. Donor 5-14 were vaccinated with yellow fever vaccine 4. Ctrl and Dis samples are donor-matched.
Lab12CTR2	27	Male	Before vaccination	
Lab12CTR3	25	Male	Before vaccination	
Lab12CTR4	25	Male	Before vaccination	
Lab12CTR5	26	Male	Before vaccination	
Lab12CTR6	29	Male	Before vaccination	
Lab12CTR7	25	Male	Before vaccination	
Lab12CTR8	25	Male	Before vaccination	
Lab12CTR9	24	Male	Before vaccination	
Lab12CTR10	24	Male	Before vaccination	
Lab12CTR11	27	Male	Before vaccination	
Lab12CTR12	26	Male	Before vaccination	
Lab12CTR13	27	Female	Before vaccination	
Lab12CTR14	27	Female	Before vaccination	

**Phase 2A**

Sample ID	AGE	SEX	Condition
Lab12CTR15	28	Male	healthy individual
Lab12CTR16	29	Male	healthy individual
Lab12CTR17	24	Female	healthy individual

**Phase 3A**

Sample ID	AGE	SEX	Condition	Notes
Lab12Dis18	25	Female	day 2 after vaccination	1. All subjects are healthy individuals 2. All donors were vaccinated with tick-borne encephalitis vaccine. 4. Ctrl and Dis samples are donor-matched.
Lab12Dis19	26	Female	day 2 after vaccination	
Lab12Dis20	30	Male	day 2 after vaccination	
Lab12Dis21	27	Male	day 2 after vaccination	
Lab12Dis22	29	Male	day 2 after vaccination	
Lab12Dis23	24	Male	day 2 after vaccination	
Lab12Dis24	29	Female	day 2 after vaccination	
Lab12Dis25	29	Male	day 2 after vaccination	
Lab12Dis26	30	Male	day 2 after vaccination	
Lab12CTR18	25	Female	Before vaccination	
Lab12CTR19	26	Female	Before vaccination	
Lab12CTR20	30	Male	Before vaccination	
Lab12CTR21	27	Male	Before vaccination	
Lab12CTR22	29	Male	Before vaccination	
Lab12CTR23	24	Male	Before vaccination	
Lab12CTR24	29	Female	Before vaccination	
Lab12CTR25	29	Male	Before vaccination	
Lab12CTR26	30	Male	Before vaccination	

## Phase 1C LAB13

Mye-MMI					1st sampling								
ID	A or B*	Age	Sex	Diagnosis	hb	CRP	Na	K	Kreatinin	Troponin	total cholesterol	HDL	glucose
Dis 1	A	77	m	atherosclerotic heart disease	15	<1	128	4,5	70	11	6	2	4,5
Dis 2	A	69	m	acute subendocardial infarction	13,3	1	137	3,9	65	1483		1,3	6,1
Dis 3	A	69	m	unstable angina	16,1	<1	141	4,3	75	25	4,6	1,3	10,6
Dis 4	A	66	m	acute subendocardial infarction		na	na	na	na	16	na	1,1	6,8
Dis 5	A	69	m	unstable angina	na	<1	na	na	na	4	na	na	na
Dis 6	A	78	f	unstable angina	na	3	na	na	na	8	na	na	na
Dis 7	A	71	m	acute subendocardial infarction	16,1	4	140	3,9	97	512	4,9	1,9	5
Dis 8	A	47	m	atherosclerotic heart disease	15,7	<1	140	4,6	75	5	3	0,9	5,8
Dis 9	A	90	m	atherosclerotic heart disease - bradycardia	12,8	<1	140	4,6	119	38	4,8	1,7	5,1
Dis 10	A	55	m	chest pain - unstable angina	15,5	4	139	4,6	85	<4	na	na	na
Ctr3	B	51	m	chest pain	10,1	7	na	na	na	10	3,8	0,9	4,9
Ctr4	B	63	m	chest pain	14	2	141		76	7	4,7	0,9	5,7
Ctr5	B	79	m	chest pain	12,4	108	139	4,3	68	23	3,3	1,4	5,9
Ctr6	B	25	m	dilated cardiomyopathy	15	<1	143	3,6	73	<4	4,6	1,4	4,8
Ctr7	B	51	m	chest pain	13,9	1	138	4,4	80	<4	5,3	2,2	5,4
Ctr8	B	67	m	chest pain	12,8	<1	144	3,8	77	<4	4,6	1,5	6,3
Ctr9	B	82	f	chest pain	12,7	2	139	4,1	112	8	5,2	2,5	5,9
Ctr10	ctr	24	f	chest pain	13,5	<1	140	3,4	77	<4	3,6	1,2	6,9
Ctr2	ctr	71	m	chest pain	14,4	3	141	4,3	50	17	4,6	1,3	10,6
Ctr1	ctr	66	f	chest pain	12,8	5	138	4,5	68	<4	6,9	0,9	6,8